High grade malignant peripheral nerve sheath tumors: Outcome of 62 patients with localized disease and review of the literature

A. Longhi, C. Errani, G. Magagnoli, M. Alberghini, M. Gambarotti, M. Mercuri, S. Ferrari

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Malignant peripheral nerve sheath tumours (MPNST) are rare sarcomas with one of the poorest prognoses of all the soft tissue sarcomas. Information about adjuvant treatment is scarce and not homogeneous for this diagnosis. We analyzed retrospectively the outcome of patients with localized high grade MPNST admitted to our Institute from 1969 to 2008. A review of the literature is also reported. Of 62 evaluable patients, 23 were females and 39 males, median age 39 years (17-71), 22/62 had neurofibromatosis type I. Median follow-up was 54 months (range 12-194). A total of 22/62 are alive; 26 patients had surgery alone, 18 received radiation therapy, 12 received radiation therapy and chemotherapy, and 6 received only adjuvant chemotherapy. The 5-year disease-free survival was 30% and 5-year overall survival was 38%. A positive trend for adjuvant radiation, but not for chemotherapy was observed according to univariate analysis only for disease-free survival and overall survival. Multivariate analysis indicated that primary site, size and surgical margins remained significant for disease-free survival and only site and size were significant for overall survival. New drugs employed successfully in advanced MPNST should be employed also in the adjuvant setting.

Original languageEnglish
Pages (from-to)413-418
Number of pages6
JournalJournal of Chemotherapy
Volume22
Issue number6
Publication statusPublished - Dec 2010

Fingerprint

Neurilemmoma
Disease-Free Survival
Sarcoma
Survival
Radiotherapy
Drug Therapy
Neurofibromatosis 1
Adjuvant Chemotherapy
Multivariate Analysis
Radiation
Pharmaceutical Preparations
Therapeutics

Keywords

  • Adjuvant treatment
  • Chemotherapy
  • MPNST
  • Schwannoma
  • Soft tissue sarcoma

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Infectious Diseases
  • Oncology
  • Pharmacology

Cite this

High grade malignant peripheral nerve sheath tumors : Outcome of 62 patients with localized disease and review of the literature. / Longhi, A.; Errani, C.; Magagnoli, G.; Alberghini, M.; Gambarotti, M.; Mercuri, M.; Ferrari, S.

In: Journal of Chemotherapy, Vol. 22, No. 6, 12.2010, p. 413-418.

Research output: Contribution to journalArticle

@article{09001370e4074c52b667551d04ecd90b,
title = "High grade malignant peripheral nerve sheath tumors: Outcome of 62 patients with localized disease and review of the literature",
abstract = "Malignant peripheral nerve sheath tumours (MPNST) are rare sarcomas with one of the poorest prognoses of all the soft tissue sarcomas. Information about adjuvant treatment is scarce and not homogeneous for this diagnosis. We analyzed retrospectively the outcome of patients with localized high grade MPNST admitted to our Institute from 1969 to 2008. A review of the literature is also reported. Of 62 evaluable patients, 23 were females and 39 males, median age 39 years (17-71), 22/62 had neurofibromatosis type I. Median follow-up was 54 months (range 12-194). A total of 22/62 are alive; 26 patients had surgery alone, 18 received radiation therapy, 12 received radiation therapy and chemotherapy, and 6 received only adjuvant chemotherapy. The 5-year disease-free survival was 30{\%} and 5-year overall survival was 38{\%}. A positive trend for adjuvant radiation, but not for chemotherapy was observed according to univariate analysis only for disease-free survival and overall survival. Multivariate analysis indicated that primary site, size and surgical margins remained significant for disease-free survival and only site and size were significant for overall survival. New drugs employed successfully in advanced MPNST should be employed also in the adjuvant setting.",
keywords = "Adjuvant treatment, Chemotherapy, MPNST, Schwannoma, Soft tissue sarcoma",
author = "A. Longhi and C. Errani and G. Magagnoli and M. Alberghini and M. Gambarotti and M. Mercuri and S. Ferrari",
year = "2010",
month = "12",
language = "English",
volume = "22",
pages = "413--418",
journal = "Journal of Chemotherapy",
issn = "1120-009X",
publisher = "Maney Publishing",
number = "6",

}

TY - JOUR

T1 - High grade malignant peripheral nerve sheath tumors

T2 - Outcome of 62 patients with localized disease and review of the literature

AU - Longhi, A.

AU - Errani, C.

AU - Magagnoli, G.

AU - Alberghini, M.

AU - Gambarotti, M.

AU - Mercuri, M.

AU - Ferrari, S.

PY - 2010/12

Y1 - 2010/12

N2 - Malignant peripheral nerve sheath tumours (MPNST) are rare sarcomas with one of the poorest prognoses of all the soft tissue sarcomas. Information about adjuvant treatment is scarce and not homogeneous for this diagnosis. We analyzed retrospectively the outcome of patients with localized high grade MPNST admitted to our Institute from 1969 to 2008. A review of the literature is also reported. Of 62 evaluable patients, 23 were females and 39 males, median age 39 years (17-71), 22/62 had neurofibromatosis type I. Median follow-up was 54 months (range 12-194). A total of 22/62 are alive; 26 patients had surgery alone, 18 received radiation therapy, 12 received radiation therapy and chemotherapy, and 6 received only adjuvant chemotherapy. The 5-year disease-free survival was 30% and 5-year overall survival was 38%. A positive trend for adjuvant radiation, but not for chemotherapy was observed according to univariate analysis only for disease-free survival and overall survival. Multivariate analysis indicated that primary site, size and surgical margins remained significant for disease-free survival and only site and size were significant for overall survival. New drugs employed successfully in advanced MPNST should be employed also in the adjuvant setting.

AB - Malignant peripheral nerve sheath tumours (MPNST) are rare sarcomas with one of the poorest prognoses of all the soft tissue sarcomas. Information about adjuvant treatment is scarce and not homogeneous for this diagnosis. We analyzed retrospectively the outcome of patients with localized high grade MPNST admitted to our Institute from 1969 to 2008. A review of the literature is also reported. Of 62 evaluable patients, 23 were females and 39 males, median age 39 years (17-71), 22/62 had neurofibromatosis type I. Median follow-up was 54 months (range 12-194). A total of 22/62 are alive; 26 patients had surgery alone, 18 received radiation therapy, 12 received radiation therapy and chemotherapy, and 6 received only adjuvant chemotherapy. The 5-year disease-free survival was 30% and 5-year overall survival was 38%. A positive trend for adjuvant radiation, but not for chemotherapy was observed according to univariate analysis only for disease-free survival and overall survival. Multivariate analysis indicated that primary site, size and surgical margins remained significant for disease-free survival and only site and size were significant for overall survival. New drugs employed successfully in advanced MPNST should be employed also in the adjuvant setting.

KW - Adjuvant treatment

KW - Chemotherapy

KW - MPNST

KW - Schwannoma

KW - Soft tissue sarcoma

UR - http://www.scopus.com/inward/record.url?scp=79958253870&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79958253870&partnerID=8YFLogxK

M3 - Article

C2 - 21303750

AN - SCOPUS:79958253870

VL - 22

SP - 413

EP - 418

JO - Journal of Chemotherapy

JF - Journal of Chemotherapy

SN - 1120-009X

IS - 6

ER -